Tuesday, April 27, 2021

MSD enters licensing pact with five Indian generic firms to manufacture, distribute COVID-19 antiviral drug molnupiravir

MSD enters licensing pact with five Indian generic firms to manufacture, distribute COVID-19 antiviral drug molnupiravir Under the agreements, MSD will provide licences to these manufacturers to supply molnupiravir to India and more than 100 LMICs. MSD is also in discussions with the Medicines Patent Pool to explore the potential for additional licences.

from Moneycontrol Business News https://ift.tt/2S1U12h
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...